DE69928500D1 - Pharmazeutische zusammensetzung enthaltend den phospholipase inhibitor natrium [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl)-1 h-indol-4-yl]oxy]acetate - Google Patents

Pharmazeutische zusammensetzung enthaltend den phospholipase inhibitor natrium [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl)-1 h-indol-4-yl]oxy]acetate

Info

Publication number
DE69928500D1
DE69928500D1 DE69928500T DE69928500T DE69928500D1 DE 69928500 D1 DE69928500 D1 DE 69928500D1 DE 69928500 T DE69928500 T DE 69928500T DE 69928500 T DE69928500 T DE 69928500T DE 69928500 D1 DE69928500 D1 DE 69928500D1
Authority
DE
Germany
Prior art keywords
dioxoethyl
phenylmethyl
indol
oxy
acetate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69928500T
Other languages
English (en)
Other versions
DE69928500T2 (de
Inventor
Lester Confer
Hideaki Tai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Eli Lilly and Co
Original Assignee
Shionogi and Co Ltd
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd, Eli Lilly and Co filed Critical Shionogi and Co Ltd
Application granted granted Critical
Publication of DE69928500D1 publication Critical patent/DE69928500D1/de
Publication of DE69928500T2 publication Critical patent/DE69928500T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DE69928500T 1998-03-03 1999-03-02 Pharmazeutische zusammensetzung enthaltend den phospholipase inhibitor natrium-[[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl)-1 h-indol-4-yl]oxy]acetat Expired - Lifetime DE69928500T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7665998P 1998-03-03 1998-03-03
US76659P 1998-03-03
PCT/US1999/004516 WO1999044604A1 (en) 1998-03-03 1999-03-02 Pharmaceutical compositions containing the phospholipase inhibitor sodium [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl)-1h-indol-4-yl]oxy]acetate

Publications (2)

Publication Number Publication Date
DE69928500D1 true DE69928500D1 (de) 2005-12-29
DE69928500T2 DE69928500T2 (de) 2006-08-03

Family

ID=22133426

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69928500T Expired - Lifetime DE69928500T2 (de) 1998-03-03 1999-03-02 Pharmazeutische zusammensetzung enthaltend den phospholipase inhibitor natrium-[[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl)-1 h-indol-4-yl]oxy]acetat

Country Status (21)

Country Link
US (1) US6166062A (de)
EP (1) EP1058547B1 (de)
JP (3) JP2002505282A (de)
KR (1) KR20010034552A (de)
CN (1) CN1299277A (de)
AT (1) ATE310513T1 (de)
AU (1) AU757002B2 (de)
BR (1) BR9908479A (de)
CA (1) CA2322796A1 (de)
DE (1) DE69928500T2 (de)
EA (1) EA003864B1 (de)
ES (1) ES2253877T3 (de)
HU (1) HUP0102812A3 (de)
ID (1) ID27487A (de)
IL (1) IL138154A0 (de)
NO (1) NO20004306L (de)
NZ (1) NZ506578A (de)
PL (1) PL342822A1 (de)
TR (1) TR200002543T2 (de)
TW (1) TW570795B (de)
WO (1) WO1999044604A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001055108A2 (en) * 2000-01-25 2001-08-02 Eli Lilly And Company Use of spl a2 inhibitors for the treatment of inflammation
EP1265607A2 (de) * 2000-03-09 2002-12-18 Eli Lilly And Company BEHANDLUNG DER RENALEN DYSFUNKTION MIT sPLA2-INHIBITOREN.
WO2002005796A2 (en) * 2000-07-14 2002-01-24 Eli Lilly And Company Use of a spla2 inhibitor for the treatment of sepsis
TWI232102B (en) 2001-07-17 2005-05-11 Shionogi & Co A pharmaceutical formulation for injection
CN1568999A (zh) * 2003-07-14 2005-01-26 南宁枫叶药业有限公司 稳定的医药用河豚毒素冷冻干燥制剂
BRPI0509592A (pt) * 2004-05-06 2007-09-25 Cydex Inc formulações de sabor mascarado, contendo sertralina e ciclodextrina de éter de sulfoalquila
PE20120476A1 (es) 2006-06-09 2012-04-20 Sanol Arznei Schwarz Gmbh Composiciones farmaceuticas estabilizadas que comprenden fesoterodina
PL2111124T3 (pl) * 2007-02-12 2012-05-31 Lassaad Boujbel Jałowy roztwór sukralozy bez środków konserwujących i sposób jego wytwarzania
JP5174365B2 (ja) * 2007-03-23 2013-04-03 第一三共株式会社 キノロン含有凍結乾燥製剤の製造方法
EP2106788A1 (de) * 2008-04-04 2009-10-07 Ipsen Pharma Flüssige und lyophilisierte Formulierungen
NZ789295A (en) 2009-04-29 2024-02-23 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
KR20140053952A (ko) * 2011-08-26 2014-05-08 제이더블유중외제약 주식회사 피라지노-트리아진 유도체를 포함하는 조성물
EP2923710A1 (de) 2014-03-27 2015-09-30 Universitätsklinikum Heidelberg Bakterielle Phospholipase-Inhibitoren als Modulatoren von Dickdarmbakterienflora

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO873860L (no) * 1986-10-31 1988-05-02 Asta Pharma Ag Ifosfamid-lyofilisat og fremgangsmaate til deres fremstilling.
JPH02207092A (ja) * 1989-02-07 1990-08-16 Kirin Brewery Co Ltd アンスラサイクリン化合物またはその塩の凍結乾燥製剤の製造法
DE69421936T2 (de) * 1993-10-27 2000-06-29 Upjohn Co Stabilisiertes prostaglandin e1
CZ82295A3 (en) * 1994-04-01 1995-12-13 Lilly Co Eli Derivative of 1h-indole-3-glyoxylamide and a pharmaceutical composition containing thereof

Also Published As

Publication number Publication date
AU757002B2 (en) 2003-01-30
BR9908479A (pt) 2000-12-05
ATE310513T1 (de) 2005-12-15
EP1058547A1 (de) 2000-12-13
TR200002543T2 (tr) 2000-11-21
WO1999044604A1 (en) 1999-09-10
WO1999044604A9 (en) 2000-01-20
DE69928500T2 (de) 2006-08-03
US6166062A (en) 2000-12-26
KR20010034552A (ko) 2001-04-25
CA2322796A1 (en) 1999-09-10
AU2799899A (en) 1999-09-20
HUP0102812A2 (hu) 2001-12-28
NO20004306D0 (no) 2000-08-29
PL342822A1 (en) 2001-07-02
IL138154A0 (en) 2001-10-31
NO20004306L (no) 2000-10-10
EA003864B1 (ru) 2003-10-30
ID27487A (id) 2001-04-12
JP2002505282A (ja) 2002-02-19
JP2011021042A (ja) 2011-02-03
EA200000897A1 (ru) 2001-02-26
ES2253877T3 (es) 2006-06-01
TW570795B (en) 2004-01-11
NZ506578A (en) 2003-09-26
EP1058547B1 (de) 2005-11-23
CN1299277A (zh) 2001-06-13
JP2006096761A (ja) 2006-04-13
HUP0102812A3 (en) 2002-01-28

Similar Documents

Publication Publication Date Title
DE69928500D1 (de) Pharmazeutische zusammensetzung enthaltend den phospholipase inhibitor natrium [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl)-1 h-indol-4-yl]oxy]acetate
BR0016555A (pt) Composições farmacêuticas que proporcionam concentrações acrescidas de droga
HUP0300850A2 (hu) Gyűrűs béta-aminosav-származékok mint mátrix metalloproteázok és a TNF-alfa inhibitorok és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
CY1107384T1 (el) Ταχεως διασπειρομενες μορφες δοσομετρησεως ανευ ζελατινης
ES2190075T3 (es) Formulaciones farmaceuticas solidas que contienen una mezcla fisica de sulfoalquil-eter-ciclodextrina y un agente terapeutico.
BR0014486A (pt) Composições farmacêuticas contendo polipeptìdeo lìquido estabilizado
DE69940354D1 (de) Adenovirus-formulierungen zur gentherapie
EA200201271A1 (ru) Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1
EA199800910A1 (ru) Композиции, комплексы включения фармацевтически приемлемой соли зипразидона и циклодекстрина и соли зипразидона
EA200000920A1 (ru) Производные бициклических гидроксамовых кислот
EA200300354A1 (ru) Хинолиноновые производные в качестве ингибиторов тирозинкиназы
ATE352354T1 (de) Kosmetische und dermatologische lichtschutzformulierungen mit einem gehalt an benzotriazolderivaten und alkylnapthalaten
ATE260658T1 (de) Pharmazeutische zubereitungen zur verminderung von atmungsdepressionen
EA200000060A1 (ru) Фармацевтические композиции для нанесения на слизистую оболочку
EA200001193A1 (ru) 2-фенил-1-[4-(2-аминоэтокси)бензил]индол в комбинации с эстрогенами
CO4940486A1 (es) Composiciones anti-fungosas
ATE404176T1 (de) Stabilisierte lyophilisierte zubereitungen mit gewebefaktor-inhibitor (tfpi) oder varianten des gewebefaktor-inhibitors
AR006523A1 (es) Compuestos ciclicos, inhibidores de la adhesion
EE200100104A (et) 5-HT4 agonisti või antagonisti uus peroraalne ravimvorm
BR0111678A (pt) Composições medicinais contendo derivados de propenona
BR0315662A (pt) Derivados de 1-(4-benzil-piperazin-1-il)-3-fenil-propenona
EA200300406A1 (ru) Фармацевтическая композиция дронедарона для парентерального введения
DE69926859D1 (de) Gebissreinigungsmittel
EA200100297A1 (ru) Моногидрат гидробромида элетриптана
BR0012184A (pt) Derivados de indol

Legal Events

Date Code Title Description
8364 No opposition during term of opposition